Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice

Sodium–glucose cotransporter 2 inhibitors for treating diabetes mellitus

Nicola Goldberg and Michael Fralick
CMAJ May 23, 2017 189 (20) E724; DOI: https://doi.org/10.1503/cmaj.161455
Nicola Goldberg
Department of Medicine (Goldberg), University of Toronto, Toronto, Ont.; Division of Pharmacoepidemiology and Pharmacoeconomics (Fralick), Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Mass.; Division of General Internal Medicine (Fralick), Department of Medicine, St Michael’s Hospital, University of Toronto, Toronto, Ont.
MD MPA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Fralick
Department of Medicine (Goldberg), University of Toronto, Toronto, Ont.; Division of Pharmacoepidemiology and Pharmacoeconomics (Fralick), Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Mass.; Division of General Internal Medicine (Fralick), Department of Medicine, St Michael’s Hospital, University of Toronto, Toronto, Ont.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Sodium–glucose cotransporter 2 inhibitors are a new class of oral drugs for treating diabetes

Sodium–glucose cotransporter 2 inhibitors (SGLT2s) are typically prescribed as a second-line agent for adults with type 2 diabetes mellitus to improve glycemic control. They reduce tubular glucose reabsorption in the proximal tubule, thereby enhancing execretion of urinary glucose. This insulin-independent mechanism provides a modest reduction in hemoglobin A1c (about 0.7%–1.0%), similar to other classes of oral drugs for treating diabetes, but with added benefits of lowering systolic blood pressure (by about 5 mm Hg) and weight loss (about 2 kg).1

Sodium–glucose cotransporter 2 inhibitors may reduce mortality in patients with type 2 diabetes at high risk for cardiovascular events

Based on a recent meta-analysis, SGLT2 inhibitors protected against cardiovascular death (relative risk [RR] 0.63, 95% confidence interval [CI] 0.51–0.77), heart failure (RR 0.65, 95% CI 0.50–0.85) and all-cause mortality (RR 0.71, 95% CI 0.61–0.83) in patients with preexisting cardiovascular disease.2 These results were mainly driven by a trial that compared empagliflozin to placebo in patients at high risk for cardiovascular events.2 It is unknown whether these findings apply to patients at lower risk. These drugs are also associated with increased low-density lipoprotein levels and an increased risk of nonfatal stroke (RR 1.30, 95% CI 1.00–1.68).2

Sodium–glucose cotransporter 2 inhibitors have a unique adverse-effect profile

Use of SGLT2 inhibitors is associated with a threefold increased risk of genital infection and may be associated with an increased risk of urinary tract infection, acute kidney injury and euglycemic diabetic ketoacidosis.1,3 Among cases reported to the United States Food and Drug Administration, diabetic ketoacidosis typically occurred within six weeks of starting treatment, and patients presented with normal or mildly elevated levels of blood glucose.3

Sodium–glucose cotransporter 2 inhibitors should be used with caution in patients on insulin, insulin secretagogues and diuretics

Coadministration of SGLT2 inhibitors with insulin or insulin secretagogues increases the risk of hypoglycemia.1 In addition, coadministration of SGLT2 inhibitors with diuretics may increase the risk of volume depletion.4 Drug–drug interactions with other drugs (e.g., digoxin and rifampin) may also exist.4

Empagliflozin, dapagliflozin and canagliflozin are available in Canada

For patients with normal renal function, the initial dosages are dapagliflozin (5 mg daily), empagliflozin (10 mg daily) and canagliflozin (100 mg daily).5 These drugs are more costly (about $80/month) than metformin ($8/month). They should not be prescribed for patients with renal impairment (i.e., renal function less than 60 mL/min/1.73 m2 for dapagliflozin and less than 45 mL/min/1.73 m2 for empagliflozin and canagliflozin).

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Vasilakou D,
    2. Karagiannis T,
    3. Athanasiadou E,
    4. et al
    . Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262–74.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Wu JHY,
    2. Foote C,
    3. Blomster J,
    4. et al
    . Effects of sodium–glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016;4:411–9.
    OpenUrlCrossRefPubMed
  3. ↵
    FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Silver Spring (MD): US Food and Drug Administration; 2015. Available: www.fda.gov/Drugs/DrugSafety/ucm475463.htm (accessed 2016 Dec. 10).
  4. ↵
    1. Scheen AJ
    . Drug–drug interactions with sodium–glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet 2014;53:295–304.
    OpenUrlCrossRefPubMed
  5. ↵
    Canagliflozin, dapagliflozin, empagliflozin. In-depth answers. Ann Arbor (MI): Truven Health Analytics; 2016. Available: www.micromedexsolutions.com (accessed 2016 Dec. 6). Login required to access content.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (20)
CMAJ
Vol. 189, Issue 20
23 May 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Sodium–glucose cotransporter 2 inhibitors for treating diabetes mellitus
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Sodium–glucose cotransporter 2 inhibitors for treating diabetes mellitus
Nicola Goldberg, Michael Fralick
CMAJ May 2017, 189 (20) E724; DOI: 10.1503/cmaj.161455

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Sodium–glucose cotransporter 2 inhibitors for treating diabetes mellitus
Nicola Goldberg, Michael Fralick
CMAJ May 2017, 189 (20) E724; DOI: 10.1503/cmaj.161455
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Sodium–glucose cotransporter 2 inhibitors are a new class of oral drugs for treating diabetes
    • Sodium–glucose cotransporter 2 inhibitors may reduce mortality in patients with type 2 diabetes at high risk for cardiovascular events
    • Sodium–glucose cotransporter 2 inhibitors have a unique adverse-effect profile
    • Sodium–glucose cotransporter 2 inhibitors should be used with caution in patients on insulin, insulin secretagogues and diuretics
    • Empagliflozin, dapagliflozin and canagliflozin are available in Canada
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SARS-CoV-2 vaccination in pregnancy
  • Infantile perianal pyramidal protrusion
  • Topical nonsteroidal anti-inflammatory drugs
Show more Practice

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire